Correlation Between Adaptive Biotechnologies and Royalty Pharma

Can any of the company-specific risk be diversified away by investing in both Adaptive Biotechnologies and Royalty Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Adaptive Biotechnologies and Royalty Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Adaptive Biotechnologies Corp and Royalty Pharma Plc, you can compare the effects of market volatilities on Adaptive Biotechnologies and Royalty Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Adaptive Biotechnologies with a short position of Royalty Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Adaptive Biotechnologies and Royalty Pharma.

Diversification Opportunities for Adaptive Biotechnologies and Royalty Pharma

0.77

Correlation Coefficient

Adaptive Biotechnologies  Royalty Pharma

Poor diversification

The 3 months correlation between Adaptive and Royalty is 0.77. Overlapping area represents the amount of risk that can be diversified away by holding Adaptive Biotechnologies Corp and Royalty Pharma Plc in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Royalty Pharma Plc and Adaptive Biotechnologies is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Adaptive Biotechnologies Corp are associated (or correlated) with Royalty Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Royalty Pharma Plc has no effect on the direction of Adaptive Biotechnologies i.e., Adaptive Biotechnologies and Royalty Pharma go up and down completely randomly.

Pair Corralation between Adaptive Biotechnologies and Royalty Pharma

Given the investment horizon of 90 days Adaptive Biotechnologies Corp is expected to generate 2.58 times more return on investment than Royalty Pharma. However, Adaptive Biotechnologies is 2.58 times more volatile than Royalty Pharma Plc. It trades about 0.09 of its potential returns per unit of risk. Royalty Pharma Plc is currently generating about 0.19 per unit of risk. If you would invest  611.00  in Adaptive Biotechnologies Corp on December 30, 2024 and sell it today you would earn a total of  156.00  from holding Adaptive Biotechnologies Corp or generate 25.53% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Adaptive Biotechnologies Corp  vs.  Royalty Pharma Plc

Adaptive Biotechnologies

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Adaptive Biotechnologies Corp are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively abnormal basic indicators, Adaptive Biotechnologies unveiled solid returns over the last few months and may actually be approaching a breakup point.

Royalty Pharma Plc

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Royalty Pharma Plc are ranked lower than 14 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unsteady basic indicators, Royalty Pharma showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Adaptive Biotechnologies and Royalty Pharma

The main advantage of trading using opposite Adaptive Biotechnologies and Royalty Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Adaptive Biotechnologies position performs unexpectedly, Royalty Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Royalty Pharma will offset losses from the drop in Royalty Pharma's long position.

The idea behind Adaptive Biotechnologies Corp and Royalty Pharma Plc pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.